Yıl: 2020 Cilt: 26 Sayı: 3 Sayfa Aralığı: 203 - 206 Metin Dili: Türkçe İndeks Tarihi: 17-02-2022

Olanzapine Bağlı Süper Refrakter Status Epileptikus Tedavisinde Vagal Sinir Stimülasyonu: Olgu Sunumu

Öz:
Olanzapin literatürde prokonvülzan risk faktörü olarak tanımlanmasına rağmen olanzapin ilişkili nöbetler nadirdir. Refrakter ve süper refrakter status epileptikus antiepileptik ilaçlarla kontrol edilemeyen status epileptikus talosudur ve kötü sonuçlarla ilişkilidir. Antiepileptik ilaçların ve anestezik ilaçların uzun süre kullanımının yan etkileri göz önünde bulundurulduğunda, vagal sinir stimulayonu gibi yan etkileri az tedavi seçeneklerine ihtiyaç vardır. Biz tedavisine olanzapin eklenmesi sonrası tonik klonik nöbetlerle gelen, vagal sinir stimulasyonu ile tedavi edilen, super refrakter status epileptikus olgumuzu sunduk
Anahtar Kelime:

Vagal Nerve Stimulation in the Treatment of Olanzapine Related Super Refractory Status Epilepticus: A Case Report

Öz:
Olanzapine-related seizures have rarely been reported despite associated proconvulsant risk factors described in the literature. Refractory and super refractory status epilepticus is continuous seizure activity not controlled by antiepileptic drugs and related poor outcomes. Because of high mortality with polypharmacy and continuous anesthetic use, there has been a considerable interest in using nonmedicinal devices like vagal nerve stimulation in aborting a seizure. In this case study, we presented a patient who developed generalized tonic-clonic seizures when olanzapine was added for psychomotor agitation and aggressiveness and super refractory status epilepticus treated using vagal nerve stimulation.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Olgu Sunumu Erişim Türü: Erişime Açık
  • 1. Rossetti AO, Lowenstein DH. Management of refractory status epilepticus in adults: still more questions than answers. Lancet Neurol 2011;10(10):922−30.
  • 2. Reznik ME, Berger K, Claassen J. Comparison of Intravenous Anesthetic Agents for the Treatment of Refractory Status Epilepticus. J Clin Med 2016;5(5):54.
  • 3. Kantanen AM, Reinikainen M, Parviainen I, Ruokonen E, Ala-Peijari M, Bäcklund T, et al. Incidence and mortality of super-refractory status epilepticus in adults. Epilepsy Behav 2015;49:131−4.
  • 4. Tian L, Li Y, Xue X, Wu M, Liu F, Hao X, et al. Super-refractory status epilepticus in West China. Acta Neurol Scand 2015;132(1):1−6. 5.
  • 5 - Jayalakshmi S, Ruikar D, Vooturi S, Alladi S, Sahu S, Kaul S, et al. Determinants and predictors of outcome in super refractory status epilepticus--a developing country perspective. Epilepsy Res 2014;108(9):1609−17.
  • 6. Holtkamp M, Othman J, Buchheim K, Masuhr F, Schielke E, Meierkord H. A “malignant” variant of status epilepticus. Arch Neurol 2005;62(9):1428−31.
  • 7. Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, et al. Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr 2016;16(1):48−61.
  • 8. Anzellotti F, Capasso M, Frazzini V, Onofrj M. Olanzapine-related repetitive focal seizures with lingual dystonia. Epileptic Disord 2016;18(1):83−6.
  • 9. Camacho A, García-Navarro M, Martínez B, Villarejo A, Pomares E. Olanzapine-induced myoclonic status. Clin Neuropharmacol 2005;28(3):145−7.
  • 10. Uvais NA, Sreeraj VS. Seizure associated with olanzapine. J Family Med Prim Care 2018;7(5):1090−2.
  • 11. Wyderski RJ, Starrett WG, Abou-Saif A. Fatal status epilepticus associated with olanzapine therapy. Ann Pharmacother 1999;33(7-8):787−9.
  • 12. Alper K, Schwartz KA, Kolts RL, Khan A. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry 2007;62(4):345−54.
  • 13. Gaspard N, Foreman BP, Alvarez V, Cabrera Kang C, Probasco JC, Jongeling AC, et al; Critical Care EEG Monitoring Research Consortium (CCEMRC). New-onset refractory status epilepticus: Etiology, clinical features, and outcome. Neurology. 2015;85(18):1604−13.
  • 14. Englot DJ, Chang EF, Auguste KI. Vagus nerve stimulation for epilepsy: a meta-analysis of efficacy and predictors of response. J Neurosurg 2011;115(6):1248−55.
  • 15. Dibué-Adjei M, Brigo F, Yamamoto T, Vonck K, Trinka E. Vagus nerve stimulation in refractory and super-refractory status epilepticus - A systematic review. Brain Stimul 2019;12(5):1101−10.
  • 16. De Herdt V, Waterschoot L, Vonck K, Dermaut B, Verhelst H, Van Coster R, et al. Vagus nerve stimulation for refractory status epilepticus. Eur J Paediatr Neurol 2009;13(3):286−9.
  • 17. Grioni D, Landi A, Fiori L, Sganzerla EP. Does emergent implantation of a vagal nerve stimulator stop refractory status epilepticus in children? Seizure 2018;61:94−7.
  • 18. Yamazoe T, Okanishi T, Yamamoto A, Yamada T, Nishimura M, Fujimoto A, et al. New-onset refractory status epilepticus treated with vagus nerve stimulation: A case report. Seizure 2017;47:1−4.
  • 19. Alsaadi T, Shakra M, Turkawi L, Hamid J. VNS terminating refractory nonconvulsive SE secondary to anti-NMDA encephalitis: a case report. Epilepsy Behav Case Rep 2015;3:39−42.
  • 20. Yazdi JS, Schumaker JA. Treatment of Refractory Status Epilepticus with Vagus Nerve Stimulator in an Elderly Patient. World Neurosurg 2016;95:620.e1−620.e7.
APA ILHAN ALGIN D, ÇAĞLAR H, aykaç ö, Vural M, ERDINC O (2020). Olanzapine Bağlı Süper Refrakter Status Epileptikus Tedavisinde Vagal Sinir Stimülasyonu: Olgu Sunumu. , 203 - 206.
Chicago ILHAN ALGIN DEMET,ÇAĞLAR HASAN,aykaç özlem,Vural Murat,ERDINC OGUZ Olanzapine Bağlı Süper Refrakter Status Epileptikus Tedavisinde Vagal Sinir Stimülasyonu: Olgu Sunumu. (2020): 203 - 206.
MLA ILHAN ALGIN DEMET,ÇAĞLAR HASAN,aykaç özlem,Vural Murat,ERDINC OGUZ Olanzapine Bağlı Süper Refrakter Status Epileptikus Tedavisinde Vagal Sinir Stimülasyonu: Olgu Sunumu. , 2020, ss.203 - 206.
AMA ILHAN ALGIN D,ÇAĞLAR H,aykaç ö,Vural M,ERDINC O Olanzapine Bağlı Süper Refrakter Status Epileptikus Tedavisinde Vagal Sinir Stimülasyonu: Olgu Sunumu. . 2020; 203 - 206.
Vancouver ILHAN ALGIN D,ÇAĞLAR H,aykaç ö,Vural M,ERDINC O Olanzapine Bağlı Süper Refrakter Status Epileptikus Tedavisinde Vagal Sinir Stimülasyonu: Olgu Sunumu. . 2020; 203 - 206.
IEEE ILHAN ALGIN D,ÇAĞLAR H,aykaç ö,Vural M,ERDINC O "Olanzapine Bağlı Süper Refrakter Status Epileptikus Tedavisinde Vagal Sinir Stimülasyonu: Olgu Sunumu." , ss.203 - 206, 2020.
ISNAD ILHAN ALGIN, DEMET vd. "Olanzapine Bağlı Süper Refrakter Status Epileptikus Tedavisinde Vagal Sinir Stimülasyonu: Olgu Sunumu". (2020), 203-206.
APA ILHAN ALGIN D, ÇAĞLAR H, aykaç ö, Vural M, ERDINC O (2020). Olanzapine Bağlı Süper Refrakter Status Epileptikus Tedavisinde Vagal Sinir Stimülasyonu: Olgu Sunumu. Epilepsi, 26(3), 203 - 206.
Chicago ILHAN ALGIN DEMET,ÇAĞLAR HASAN,aykaç özlem,Vural Murat,ERDINC OGUZ Olanzapine Bağlı Süper Refrakter Status Epileptikus Tedavisinde Vagal Sinir Stimülasyonu: Olgu Sunumu. Epilepsi 26, no.3 (2020): 203 - 206.
MLA ILHAN ALGIN DEMET,ÇAĞLAR HASAN,aykaç özlem,Vural Murat,ERDINC OGUZ Olanzapine Bağlı Süper Refrakter Status Epileptikus Tedavisinde Vagal Sinir Stimülasyonu: Olgu Sunumu. Epilepsi, vol.26, no.3, 2020, ss.203 - 206.
AMA ILHAN ALGIN D,ÇAĞLAR H,aykaç ö,Vural M,ERDINC O Olanzapine Bağlı Süper Refrakter Status Epileptikus Tedavisinde Vagal Sinir Stimülasyonu: Olgu Sunumu. Epilepsi. 2020; 26(3): 203 - 206.
Vancouver ILHAN ALGIN D,ÇAĞLAR H,aykaç ö,Vural M,ERDINC O Olanzapine Bağlı Süper Refrakter Status Epileptikus Tedavisinde Vagal Sinir Stimülasyonu: Olgu Sunumu. Epilepsi. 2020; 26(3): 203 - 206.
IEEE ILHAN ALGIN D,ÇAĞLAR H,aykaç ö,Vural M,ERDINC O "Olanzapine Bağlı Süper Refrakter Status Epileptikus Tedavisinde Vagal Sinir Stimülasyonu: Olgu Sunumu." Epilepsi, 26, ss.203 - 206, 2020.
ISNAD ILHAN ALGIN, DEMET vd. "Olanzapine Bağlı Süper Refrakter Status Epileptikus Tedavisinde Vagal Sinir Stimülasyonu: Olgu Sunumu". Epilepsi 26/3 (2020), 203-206.